Concordance Between Biochemical and Molecular Diagnosis Obtained by WES in Mexican Patients with Inborn Errors of Intermediary Metabolism: Utility for Therapeutic Management

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Nov 9

PMID 39519275

Authors

Marcela Vela-Amieva

Miguel Angel Alcantara-Ortigoza

Ariadna Gonzalez-Del Angel

Liliana Fernandez-Hernandez

Miriam Erandi Reyna-Fabian

Bernardette Estandia-Ortega

Sara Guillen-Lopez

Lizbeth Lopez-Mejia

Leticia Belmont-Martinez

Rosa Itzel Carrillo-Nieto

Isabel Ibarra-Gonzalez

Seung-Woo Ryu

Hane Lee

Cynthia Fernandez-Lainez

Affiliations

Soon will be listed here.

Abstract

Biochemical phenotyping has been the milestone for diagnosing and managing patients affected by inborn errors of intermediary metabolism (IEiM); however, identifying the genotype responsible for these monogenic disorders greatly contributes to achieving these goals. Herein, whole-exome sequencing (WES) was used to determine the genotypes of 95 unrelated Mexican pediatric patients suspected of having IEiM. They were classified into those bearing specific biochemical abnormalities (Group 1), and those presenting unspecific biochemical profiles (Group 2). The overall concordance between the initial biochemical diagnosis and final genotypic diagnoses was 72.6% ( = 69/95 patients), with the highest concordance achieved in Group 1 (91.3%, = 63/69), whereas the concordance was limited in Group 2 (23.07%). This finding suggests that previous biochemical phenotyping correlated with the high WES diagnostic success. Concordance was high for urea cycle disorders (94.1%) and organic acid disorders (77.4%). The identified mutational spectrum comprised 83 IEiM-relevant variants (pathogenic, likely pathogenic, and variants of uncertain significance or VUS), including three novel ones, distributed among 29 different genes responsible for amino acid, organic acid, urea cycle, carbohydrate, and lipid disorders. Inconclusive WES results (7.3%, = 7/95) relied on monoallelic pathogenic genotypes or those involving two VUS for autosomal-recessive IEiMs. A second monogenic disease was observed in 10.5% ( = 10/95) of the patients. According to the WES results, modifications in treatment had to be made in 33.6% ( = 32/95) of patients, mainly attributed to the presence of a second monogenic disease, or to an actionable trait. This study includes the largest cohort of Mexican patients to date with biochemically suspected IEiM who were genetically diagnosed through WES, underscoring its importance in medical management.

References

Schobers G, Schieving J, Yntema H, Pennings M, Pfundt R, Derks R . Reanalysis of exome negative patients with rare disease: a pragmatic workflow for diagnostic applications. Genome Med. 2022; 14(1):66. PMC: 9204949. DOI: 10.1186/s13073-022-01069-z. View

Farwell K, Shahmirzadi L, El-Khechen D, Powis Z, Chao E, Davis B . Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med. 2014; 17(7):578-86. DOI: 10.1038/gim.2014.154. View

Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y . Mutations in the holocarboxylase synthetase gene HLCS. Hum Mutat. 2005; 26(4):285-90. DOI: 10.1002/humu.20204. View

Miller D, Lee K, Chung W, Gordon A, Herman G, Klein T . ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021; 23(8):1381-1390. DOI: 10.1038/s41436-021-01172-3. View

Marom D, Mory A, Reytan-Miron S, Amir Y, Kurolap A, Cohen J . National Rapid Genome Sequencing in Neonatal Intensive Care. JAMA Netw Open. 2024; 7(2):e240146. PMC: 10884880. DOI: 10.1001/jamanetworkopen.2024.0146. View

Karczewski K, Francioli L, Tiao G, Cummings B, Alfoldi J, Wang Q . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443. PMC: 7334197. DOI: 10.1038/s41586-020-2308-7. View

Soriano-Sexto A, Gallego D, Leal F, Castejon-Fernandez N, Navarrete R, Alcaide P . Identification of Clinical Variants beyond the Exome in Inborn Errors of Metabolism. Int J Mol Sci. 2022; 23(21). PMC: 9654865. DOI: 10.3390/ijms232112850. View

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J . Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5):405-24. PMC: 4544753. DOI: 10.1038/gim.2015.30. View

Shakiba M, Keramatipour M . Effect of Whole Exome Sequencing in Diagnosis of Inborn Errors of Metabolism and Neurogenetic Disorders. Iran J Child Neurol. 2018; 12(1):7-15. PMC: 5760669. View

10.

Kose M, Isik E, Aykut A, Durmaz A, Kose E, Ersoy M . The utility of next-generation sequencing technologies in diagnosis of Mendelian mitochondrial diseases and reflections on clinical spectrum. J Pediatr Endocrinol Metab. 2021; 34(4):417-430. DOI: 10.1515/jpem-2020-0410. View

11.

Zhang R, Qiang R, Song C, Ma X, Zhang Y, Li F . Spectrum analysis of inborn errors of metabolism for expanded newborn screening in a northwestern Chinese population. Sci Rep. 2021; 11(1):2699. PMC: 7846761. DOI: 10.1038/s41598-021-81897-y. View

12.

Morava E, Baumgartner M, Patterson M, Peters V, Rahman S . Newborn screening: To WES or not to WES, that is the question. J Inherit Metab Dis. 2020; 43(5):904-905. DOI: 10.1002/jimd.12303. View

13.

Green R, Berg J, Grody W, Kalia S, Korf B, Martin C . ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15(7):565-74. PMC: 3727274. DOI: 10.1038/gim.2013.73. View

14.

Migliavacca M, Sobreira J, Bermeo D, Gomes M, Alencar D, Sussuchi L . Whole genome sequencing as a first-tier diagnostic test for infants in neonatal intensive care units: A pilot study in Brazil. Am J Med Genet A. 2024; 194(6):e63544. DOI: 10.1002/ajmg.a.63544. View

15.

Kohler S, Schulz M, Krawitz P, Bauer S, Dolken S, Ott C . Clinical diagnostics in human genetics with semantic similarity searches in ontologies. Am J Hum Genet. 2009; 85(4):457-64. PMC: 2756558. DOI: 10.1016/j.ajhg.2009.09.003. View

16.

Suzuki H, Nozaki M, Yoshihashi H, Imagawa K, Kajikawa D, Yamada M . Genome Analysis in Sick Neonates and Infants: High-yield Phenotypes and Contribution of Small Copy Number Variations. J Pediatr. 2022; 244:38-48.e1. DOI: 10.1016/j.jpeds.2022.01.033. View

17.

Greene D, Richardson S, Turro E . Phenotype Similarity Regression for Identifying the Genetic Determinants of Rare Diseases. Am J Hum Genet. 2016; 98(3):490-499. PMC: 4827100. DOI: 10.1016/j.ajhg.2016.01.008. View

18.

Dharmadhikari A, Ghosh R, Yuan B, Liu P, Dai H, Al Masri S . Copy number variant and runs of homozygosity detection by microarrays enabled more precise molecular diagnoses in 11,020 clinical exome cases. Genome Med. 2019; 11(1):30. PMC: 6525387. DOI: 10.1186/s13073-019-0639-5. View

19.

Adhikari A, Gallagher R, Wang Y, Currier R, Amatuni G, Bassaganyas L . The role of exome sequencing in newborn screening for inborn errors of metabolism. Nat Med. 2020; 26(9):1392-1397. PMC: 8800147. DOI: 10.1038/s41591-020-0966-5. View

20.

Shickh S, Mighton C, Uleryk E, Pechlivanoglou P, Bombard Y . The clinical utility of exome and genome sequencing across clinical indications: a systematic review. Hum Genet. 2021; 140(10):1403-1416. DOI: 10.1007/s00439-021-02331-x. View